Search | TVST | ARVO Journals

View

Showing 1 – 7 of 7

SORT: Best Match Most Recent Oldest

VIEW: Basic | Expanded

Retina October 2022

Evaluation of Molecular Properties versus In Vivo Performance of Aflibercept, Brolucizumab, and Ranibizumab in a Retinal Vascular Hyperpermeability Model

PDF

William Schubert; Carsten Terjung; Ashique Rafique; Carmelo Romano; Philipp Ellinger; Kay D. Rittenhouse
TAGS: aflibercept, brolucizumab, oryctolagus cuniculus, ranibizumab, vascular endothelial growth factor a, anti-vascular endothelial growth factor therapy, calcium
Trans. Vis. Sci. Tech.. 2022; 11(10):36. doi: https://doi.org/10.1167/tvst.11.10.36

Includes: Supplemental Content

ARVO Annual Meeting Abstract June 2021

Neuroprotective and Anti-Inflammatory Effects of a Novel Soluble Guanylate Cyclase Activator Runcaciguat in Ischemic Retinal Disease Animal Models

Elia J Duh; William Schubert; Zhenhua Xu; Carsten Terjung; Hongkwan Cho; Lingli Zhou; Lijuan Wu; James Guerra; Khaled Nassar

Invest. Ophthalmol. Vis. Sci.. 2021; 62(8):1078. doi:

ARVO Annual Meeting Abstract June 2021

Retinal vascular effects of novel soluble guanylate cyclase activator (sGCa) runcaciguat

Khaled Nassar; William Schubert; Zhenhua Xu; Carsten Terjung; Lingli Zhou; James Guerra; Katja Rheindorf; Hanna M. Eilken; Elia J Duh

Invest. Ophthalmol. Vis. Sci.. 2021; 62(8):3002. doi:

ARVO Annual Meeting Abstract June 2020

Development of injectable long-acting controlled release intravitreal depot of BAY224 using biodegradable silica microparticle-silica hydrogel composite

Panu Noppari; Ari-Pekka Forsback; Carsten Terjung; Aarne Marttila; Lasse Leino; Florian Unger; Lars Baerfacker; Frederic Dargelas; Marcus Reay

Invest. Ophthalmol. Vis. Sci.. 2020; 61(7):1357. doi:

ARVO Annual Meeting Abstract July 2018

P2X7R inhibition activates autophagy and impairs the inflammasome response in the RPE

James T Handa; Hanna Eilken; Charles Eberhart; Marcus Karlstetter; Hartmut Schirok; Meysam Yazdankhah; Peng Shang; Marisol del Valle Cano; Jeff S Mumm; Alexander Zink; Carsten Terjung; Bernd Kalthof; Debasish Sinha

Invest. Ophthalmol. Vis. Sci.. 2018; 59(9):64. doi:

ARVO Annual Meeting Abstract July 2018

Identification of a retinal neuroprotective kinase inhibitor with preferential activity against DLK compared to LZK

Derek Stuart Welsbie; Hartmut Schirok; Katherine Mitchell; Michael Koch; Byung-Jin Kim; Mario Lobell; Amit K Patel; Simon Holton; Dmitrij Hristodorov; Julian Esteve-Rudd; Cynthia Berlinicke; Carsten Terjung; Baranda S. Hansen; Nicolas Werbeck; William Schubert; Donald J Zack

Invest. Ophthalmol. Vis. Sci.. 2018; 59(9):2493. doi:

ARVO Annual Meeting Abstract July 2018

Evaluation of a new pharmacologic strategy for Nrf2 activation for retinal ischemia-reperfusion injury

Elia J Duh; Marcus Karlstetter; Zhenhua Xu; Junsong Gong; Hongkwan Cho; Jing Yang; Hartmut Schirok; Linn Schneider; Mario Lobell; Martina Schaefer; Carsten Terjung; Khaled Nassar

Invest. Ophthalmol. Vis. Sci.. 2018; 59(9):3203. doi:

Advertisement